Sistema de Salut de Catalunya
Institut Català de la Salut
[González-Juanatey JR] Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain. [Górriz JL] Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. [Ortiz A] Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain. [Valle A] Cardiology Department, Hospital La Salud, Valencia, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Facila L] Cardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-03-03T13:33:11Z
2023-03-03T13:33:11Z
2023-01-31
Albuminuria; Enfermedad renal crónica; Finerenona
Albuminúria; Malaltia renal crònica; Finerenona
Albuminuria; Chronic kidney disease; Finerenone
Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.
Article
Published version
English
Diabetis no-insulinodependent - Complicacions; Insuficiència renal crònica - Complicacions; Sistema cardiovascular - Malalties - Diagnòstic; Antihormones; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2; DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic; DISEASES::Cardiovascular Diseases; CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Mineralocorticoid Receptor Antagonists; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II; ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica; ENFERMEDADES::enfermedades cardiovasculares; COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de receptores de mineralocorticoides; Otros calificadores::Otros calificadores::/uso terapéutico
Taylor & Francis
Annals of Medicine;55(1)
https://doi.org/10.1080/07853890.2023.2171110
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3437]
